Pharmaceutical Industry in France
Uploaded by
somethingPharmaceutical Industry in France
Uploaded by
somethingPHARMA &
BIOPHARMA
IN FRANCE
key info in
10
points
1
THE WORLD’S 5TH LARGEST
PHARMA MARKET
France is the fifth largest market in the world for human
medicines, and the second largest in Europe. In 2015, revenues
from pharmaceuticals exceeded €53 billion, nearly half of
which were generated by exports. (LEEM Pharmaceutical
Industry Association, 2016)
2
SANOFI: AN INNOVATIVE LEADER
Sanofi is the third largest healthcare firm in the world, ranking
19th among multinationals for research investment (The 2015
EU Industrial R&D Investment Scoreboard). One of its products,
Dengvaxia, is the world’s first approved dengue vaccine, with
100 million doses produced every year in France.
3
FRANCE’S PROWESS
IN VACCINES
France is a leading player in the global vaccines market, with
world-renowned institutions such as the Institut Pasteur
International Network (RIIP), totaling 23,000 personnel
overseeing 768 projects at 33 establishments in 26 countries on
every continent. The RIIP plays a major role in particular against
emerging infections wherever they occur across the globe.
4
€25 BILLION IN
PHARMACEUTICAL EXPORTS
French pharmaceutical exports rose 1.5% from 2014 to
€25.4 billion in 2015. The EU was the most frequent destination
(€14 billion, 57%), ahead of America (15.3%), Africa (12.3%),
Asia (11%), and the Middle East (4.1%). Germany (€2.7 billion),
Belgium (€2.6 billion) and the United States (€2.5 billion) were
the three leading countries. (LEEM Pharmaceutical Industry
Association, 2016)
5
WORLD-CLASS
EXCELLENCE
France’s global market share in pharmaceutical
exports was 6.1% in 2015 (UN Comtrade), while in
2016 France’s trade balance in the sector generated
a surplus of €3.9 billion. Pharmaceutical products
accounted for 6.6% of French exports in 2016. (French
Customs Authorities)
6
TEMPORARY
AUTHORIZATION FOR USE
Pharmaceutical specialties whose efficacy and safe
use can be assumed, but which have not yet obtained
market approval or been tested in clinical trials, may
nevertheless be granted temporary authorization for
use (Autorisation temporaire d’utilisation – ATU) in
exceptional circumstances as a last resort.
7
A SECTOR CREATING
SKILLED JOBS
Nearly 99,000 people are employed directly by
pharmaceutical companies in France, including 42,000
in manufacturing operations. Fifty percent of the
20,000 people working in R&D hold a research position.
(LEEM Pharmaceutical Industry Association, 2016)
8
INVESTING IN RESEARCH
The pharmaceutical industry has one of the highest
business enterprise R&D budgets of any sector in France,
accounting for 9.8% of pharmaceutical company revenues.
(LEEM Pharmaceutical Industry Association, 2016)
9
ASTRAZENECA INVESTING
€135 BILLION IN FRANCE
In 1990, Anglo-Swedish company AstraZeneca first set
up operations in Dunkirk (Hauts de France region), where
it currently employs 450 people to produce two asthma
medicines. In 2016, the firm invested €135 million at the
site, which exports 90% of its output throughout the world.
10
FRANCE RANKED #1 FOR
VETERINARY PRODUCTS
France is the leading country in Europe for research and
production of veterinary products and reagents, with
revenues in the French market amounting to €833 million,
and export sales adding a further €1.2 billion (including
€700 million within the EU). French companies Merial,
Virbac, Ceva and Vetoquinol are ranked among the
10 leading laboratories in the world. (SIMV Veterinary
Medicine Industry Association, 2015)
For further information, please visit:
www.businessfrance.fr
- May 2017
Designed and produced by:
Business France
77, boulevard Saint-Jacques
75680 Paris Cedex 14 - France
Tel.: +33 1 40 73 30 00
FRANCE:
#1
in the world for life
expectancy at 65 years
(OECD, 2015)
52
job-creating foreign investment
projects in the French
healthcare sector in 2016
(Business France)
France: the world’s
5th
largest market for
human medicines
(LEEM Pharmaceutical Industry Association, 2016)
France:
inventor of the world’s
1 st
approved dengue
vaccine
